Angela Trejo Nogales

Dr. Angela Trejo Nogales

Organic Chemistry I, University of the Basque Country UPV/EHU, Vitoria-Gasteiz, Basque Country, Spain
orcid
Postdoctoral researcher

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Open access
MFMaría Fuertes
María Fuertes
ASAsier Selas
Asier Selas
Angela Trejo NogalesAngela Trejo Nogales
Angela Trejo Nogales
BKBirgitta R. Knudsen
Birgitta R. Knudsen
FPFrancisco Palacios
Francisco Palacios
Concepcion AlonsoConcepcion Alonso
Concepcion Alonso
This work describes the first synthesis of diethyl 6,6a,7,11b-tetrahydro-5H-indeno[2,1-c]quinolinylphosphonates 5, diethyl 7H-indeno[2,1-c]quinolinylphosphonates 6 and diethyl 7-oxo-7H-indeno[2,1-c]quinolinylphosphonates 7, which were prepared in good to high overall yields. The synthetic route involves a multicomponent reaction of 2-phosphonateaniline, aldehydes and indene as olefin and allows the selective generation of three stereogenic centres in a short, efficient and reliable manner. The selective dehydrogenation of 1,2,3,4-tetrahydroindenoquinolines leads to the formation of corresponding indenoquinolines, and subsequent oxidation of methylene group of the indenoquinolines allows the access to indenoquinolinones.

23 April 2025 in European Journal of Medicinal Chemistry
Verified
Journal Article
Open access
LSLeonardo Sandin-Mazzondo
Leonardo Sandin-Mazzondo
Angela Trejo NogalesAngela Trejo Nogales
Angela Trejo Nogales
MMMariachiara Mammone
Mariachiara Mammone
MPMaria Grazia Perrone
Maria Grazia Perrone
MCMarialessandra Contino
Marialessandra Contino
CBCamino Bartolomé
Camino Bartolomé
This work is focused on the synthesis and biological evaluation of 4,5-diazafluorene bipyridines and their silver(I) complexes. These 4,5-diazafluorene derivatives have two aromatic R groups at the C9 position (R = 4-C6H4X, X = H, 3; Me, 4; NH2, 5; OH, 6; OMe, 7; Br, 8; F, 11; Cl, 12; I, 13; R = 3-Me-4-NH2-C6H3, 9; 3,5-Me2-4-NH2-C6H2, 10). Their synthesis was carried out from a direct SEAr from 4,5-diazafluoren-9-one and the corresponding aryl compound or via the diazonium salt strategy. These compounds were used as ligands to synthesize [Ag(N-N)2]NO3 complexes (3Ag-13Ag). The stability of these complexes in DMSO solution was studied showing that no dissociation was observed over 48 h. All compounds were characterized by NMR (1H and 13C) and MS. The crystal structures of three complexes were determined by single-crystal X-ray diffraction revealing different coordination geometries in solid state. The cytotoxicity study of the compounds was analyzed in lung carcinoma (A-549), cervical carcinoma (HeLa), melanoma (HBT70) cancerous cell lines and in non-malignant lung fibroblasts (MRC-5) and normal human dermal fibroblasts (HDFn) cell lines. Only ligands 3, 7, 11, and 13 exhibited antiproliferative activity. On the other hand, most of the complexes were active suggesting a positive impact when silver is incorporated into the molecule. The selectivity index towards cancerous cells was calculated. Values from 3 to more than 16 were obtained suggesting that these silver complexes are promising molecules for future anticancer treatments. Drug-likeness and ADME properties were in silico calculated for the ligands. The P-gp interaction and Papp were experimentally evaluated. Regarding their action, ROS production does not appear to be the main mechanism by which these complexes exert their cytotoxicity, nor do they appear to be DNA intercalators or DNA covalent binders.

3 January 2023 in Antibiotics
Verified
Journal Article
Open access
PDF file
Angela Trejo NogalesAngela Trejo Nogales
Angela Trejo Nogales
CMCarme Masdeu
Carme Masdeu
ISIrene Serrano-Pérez
Irene Serrano-Pérez
MTMarina Pedrola Teixell
Marina Pedrola Teixell
NJNarcís Juanola
Narcís Juanola
Miguel VinasMiguel Vinas
Miguel Vinas
New antibiotic agents were prepared using Povarov and Ugi multicomponent reactions upon the known drugs sulfadoxine and dapsone. The prepared derivatives, with increased lipophilicity, showed improved efficiency against Mycolata bacteria. Microbiological guidance for medicinal chemistry is a powerful tool to design new and effective antimicrobials. In this case, the readily synthesized compounds open new possibilities in the search for antimicrobials active on mycolic acid-containing bacteria.

27 April 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
JKJosephine Keller
Josephine Keller
KPKamilla Vandsø Petersen
Kamilla Vandsø Petersen
KMKarol Mizielinski
Karol Mizielinski
CTCeline Thiesen
Celine Thiesen
LBLotte Bjergbæk
Lotte Bjergbæk
CTCinzia Tesauro
Cinzia Tesauro
With the increasing need for effective compounds against cancer or pathogen-borne diseases, the development of new tools to investigate the enzymatic activity of biomarkers is necessary. Among these biomarkers are DNA topoisomerases, which are key enzymes that modify DNA and regulate DNA topology during cellular processes. Over the years, libraries of natural and synthetic small-molecule compounds have been extensively investigated as potential anti-cancer, anti-bacterial, or anti-parasitic drugs targeting topoisomerases. However, the current tools for measuring the potential inhibition of topoisomerase activity are time consuming and not easily adaptable outside specialized laboratories. Here, we present rolling circle amplification-based methods that provide fast and easy readouts for screening of compounds against type 1 topoisomerases. Specific assays for the investigation of the potential inhibition of eukaryotic, viral, or bacterial type 1 topoisomerase activity were developed, using human topoisomerase 1, Leishmania donovani topoisomerase 1, monkeypox virus topoisomerase 1, and Mycobacterium smegmatis topoisomerase 1 as model enzymes. The presented tools proved to be sensitive and directly quantitative, paving the way for new diagnostic and drug screening protocols in research and clinical settings.

16 July 2025 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
Angela Trejo NogalesAngela Trejo Nogales
Angela Trejo Nogales
YAYunuen Avalos-Padilla
Yunuen Avalos-Padilla
CAConcepción Alonso
Concepción Alonso
Xavier Fernàndez-BusquetsXavier Fernàndez-Busquets
Xavier Fernàndez-Busquets
CMCarme Masdeu
Carme Masdeu